Wellington Management Group LLP Trims Stock Position in ICU Medical, Inc. $ICUI

Wellington Management Group LLP lessened its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 38.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 148,986 shares of the medical instruments supplier’s stock after selling 94,135 shares during the quarter. Wellington Management Group LLP’s holdings in ICU Medical were worth $21,841,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Allworth Financial LP acquired a new position in shares of ICU Medical in the second quarter worth about $26,000. Hilton Head Capital Partners LLC purchased a new position in shares of ICU Medical in the fourth quarter valued at approximately $32,000. Public Employees Retirement System of Ohio purchased a new position in ICU Medical in the 2nd quarter valued at $51,000. Covestor Ltd lifted its stake in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 126 shares in the last quarter. Finally, Strs Ohio lifted its stake in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on ICUI. KeyCorp lifted their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Needham & Company LLC raised their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Piper Sandler increased their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $167.58 on Monday. The stock has a market cap of $4.19 billion, a P/E ratio of 142.02, a P/E/G ratio of 2.12 and a beta of 0.75. The stock has a 50 day moving average of $167.35 and a two-hundred day moving average of $144.86. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a twelve month low of $112.50 and a twelve month high of $192.85.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period last year, the firm posted $2.10 EPS. ICU Medical’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts forecast that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Insider Activity

In other ICU Medical news, VP Daniel Woolson sold 5,417 shares of ICU Medical stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the sale, the vice president owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares in the company, valued at approximately $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 21,830 shares of company stock valued at $3,905,003. 2.10% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.